Evidence map›Paper›PMID 36611902›Full record

ArticleCells2022

Nicotinamide Mononucleotide Administration Prevents Doxorubicin-Induced Cardiotoxicity and Loss in Physical Activity in Mice.

Marielle Margier, Chisaka Kuehnemann, Nicolas Hulo, Jazmin Morales, Prasanna Vadhana Ashok Kumaar, Cecile Cros, Helene Cannelle, Julie Charmetant, Eric Verdin, Matthias Canault and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NADRedox report : communications in free radical research · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. NADCell communication and signaling : CCS · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Generation of a p21 Reporter Mouse and Its Use to Identify and Eliminate p21International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Marielle MargierLGD SARL, 13880 Velaux, France.
Chisaka KuehnemannBuck Institute for Research on Aging, Novato, CA 94945, USA.
Nicolas HuloNuvamid SA, 1260 Nyon, Switzerland.
Jazmin MoralesBuck Institute for Research on Aging, Novato, CA 94945, USA.
Prasanna Vadhana Ashok KumaarBuck Institute for Research on Aging, Novato, CA 94945, USA.
Cecile CrosNuvamid SA, 1260 Nyon, Switzerland.
Helene CannelleNuvamid SA, 1260 Nyon, Switzerland.
Julie CharmetantLGD SARL, 13880 Velaux, France.
Eric VerdinBuck Institute for Research on Aging, Novato, CA 94945, USA.ORCID 0000-0003-3703-3183
Matthias CanaultLGD SARL, 13880 Velaux, France.ORCID 0000-0002-7880-5250
Alessia GrozioBuck Institute for Research on Aging, Novato, CA 94945, USA.ORCID 0000-0003-4699-3303
Buck Institute for Research on Aging · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (Doxo) is a widely used antineoplastic drug with limited clinical application due to its deleterious dose-related side effects. We investigated whether nicotinamide mononucleotide (NMN) could protect against Doxo-induced cardiotoxicity and physical dysfunction in vivo. To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic. In the acute study, C57BL6/J (B6) mice were injected intraperitoneally (i.p.) once with Doxo (20 mg/kg) and NMN (180 mg/kg/day, i.p.) was administered daily for five days before and after the Doxo injection. In the chronic study, B6 mice received a cumulative dose of 20 mg/kg Doxo administered in fractionated doses for five days. NMN (500 mg/kg/day) was supplied in the mice's drinking water beginning five days before the first injection of Doxo and continuing for 60 days after. We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models. In addition, NMN protected against Doxo-induced cardiotoxicity and loss of physical function in acute and chronic studies, respectively. In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways. Overall, our results suggest that NMN could prevent Doxo-induced toxicity in heart and skeletal muscle.

Indexed as

CardiotoxicityNicotinamide MononucleotideAnimalsApoptosisDoxorubicinHeartMiceDoxorubicinNicotinamide Mononucleotidecardiotoxicitydoxorubicininflammationmitochondrial functionsNAD+nicotinamide mononucleotideoxidative stressp53-mediated pathwaysphysical activity impairment

Identifiers

PMID36611902
PMCPMC9818647
OpenAlexW4313415397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.